Hadas completed her master at Ben-Gurion University, where she specialized in cancer metabolism and mitochondrial apoptosis pathways, and received her PhD at the Hebrew University of Jerusalem, where she focused on the role of CD48, an activator receptor expressed on mast cells, during allergic inflammation and SARS-CoV-2 infection. Prior to her PhD, she worked as a scientist at ViDAC Pharma Ltd., a clinical-stage biopharmaceutical company that develops small molecules for the treatment of oncologic and dermatologic diseases. Her current research focuses on understanding the mechanism behind the migration and expansion of mast cells during pulmonary inflammation. In her free time, Hadas enjoy nature, reading books, meditations and acting classes.